Text Size
44 studies found for:    INCB018424 | Exclude Unknown

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Not yet recruiting Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Condition: Leukemia
Interventions: Drug: Ruxolitinib;   Drug: TKI
2 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
3 Completed A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: INCB018424 phosphate cream;   Drug: Dovonex® calcipotriene 0.005%;   Drug: Diprolene® AF betamethasone dipropionate 0.05% cream.;   Drug: Placebo cream
4 Active, not recruiting
Has Results 		Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Ruxolitinib
5 Recruiting Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
6 Terminated
Has Results 		Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Intervention: Drug: Ruxolitinib
7 Active, not recruiting
Has Results 		Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Thrombocytosis
Intervention: Drug: Ruxolitinib
8 Active, not recruiting INCB018424 in Patients With Advanced Hematologic Malignancies
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia
Intervention: Drug: INCB018424
9 Recruiting Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Lenalidomide;   Drug: Prednisone
10 Completed
Has Results 		A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Ruxolitinib 25 mg;   Drug: Dexamethasone 40 mg
11 Active, not recruiting
Has Results 		COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Placebo
12 Completed Study of INCB018424 Sustained Release Formulation in Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Drug: INCB018424 (ruxolitinib)
13 Recruiting A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Condition: Myelomonocytic Leukemia
Intervention: Drug: Ruxolitinib
14 Recruiting Ruxolitinib in Patients With Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Ruxolitinib
15 Active, not recruiting Phase l/II Study of Ruxolitinib for Acute Leukemia
Condition: Leukemia
Intervention: Drug: Ruxolitinib
16 Recruiting Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
17 Recruiting Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
Conditions: Peripheral T-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma
Interventions: Drug: oral JAK inhibitor INCB18424;   Other: laboratory biomarker analysis;   Other: pharmacological study
18 Completed A Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: INCB018424 Phosphate Cream;   Drug: Placebo Cream
19 Recruiting Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Conditions: Anemia;   Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: ruxolitinib phosphate;   Drug: danazol
20 Recruiting Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib and HU-placebo;   Drug: HU and ruxolitinib-placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years